Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Withdrawn Phase 2 Trials for Venetoclax (DB11581)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04285268Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaTreatment